Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-small-cell lung cancer: how to manage RET-positive disease
Elisa Andrini, Mirta Mosca, Linda Galvani, et al.
Drugs in Context (2022) Vol. 11, pp. 1-12
Open Access | Times Cited: 12

Showing 12 citing articles:

Design, synthesis and evaluation of (E)-1-(4-(2-(1H-pyrazol-5-yl)vinyl)phenyl) derivatives as next generation selective RET inhibitors overcoming RET solvent front mutations (G810C/R)
Minghui Xu, Kaifu Wu, Rui He, et al.
European Journal of Medicinal Chemistry (2025), pp. 117294-117294
Closed Access
Targeted therapeutic options in early and metastatic NSCLC-overview
Gabriella Gálffy, Éva Morócz, Réka Korompay, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 3
Precision nanomedicine to treat non-small cell lung cancer
Akanksha Dessai, Usha Y. Nayak, Yogendra Nayak
Life Sciences (2024) Vol. 346, pp. 122614-122614
Open Access | Times Cited: 3
A MEK inhibitor arrests the cell cycle of human conjunctival fibroblasts and improves the outcome of glaucoma filtration surgery
Jin‐Hee Lee, Megumi Honjo, Makoto Aihara
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report
Daniela Scattolin, Elena Scagliori, Antonio Scapinello, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Lung Cancer
Guy Berchem, Solange Peters
Springer eBooks (2024), pp. 1-29
Closed Access
Lung Adenocarcinoma Systems Biomarker and Drug Candidates Identified by Machine Learning, Gene Expression Data, and Integrative Bioinformatics Pipeline
Semra Melis Soyer, Pemra Özbek, Ceyda Kasavi
OMICS A Journal of Integrative Biology (2024) Vol. 28, Iss. 8, pp. 408-420
Closed Access
Long-term safety of selpercatinib for Rearrenged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time
Luis E. Raez, Ashish C. Massey, Scott Barker, et al.
The Oncologist (2024) Vol. 29, Iss. 12, pp. 1068-1078
Open Access
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
Andrea De Giglio, Biagio Ricciuti, Giulio Metro
Drugs in Context (2023) Vol. 12, pp. 1-3
Open Access | Times Cited: 1
Challenges and opportunities for treating intrahepatic cholangiocarcinoma: targeted therapy
Gahyun Gim, Nabeel Badri
Hepatoma Research (2023)
Open Access | Times Cited: 1
Construction of a multiple-class classifier based on mRNAs and lncRNA FAM66A and PSORS1C3 for predicting distant metastasis in lung adenocarcinoma
Guo-Yong Lin, Zhisen Gao, Xiaohong Zheng, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 20, pp. 1129-1129
Open Access | Times Cited: 1
A Rare Case of Pulmonary Metastasis Exhibiting a Dual Phenotype of Cholangiocarcinoma and Pulmonary Adenocarcinoma: Emphasizing the Necessity for Meticulous Surveillance and Timely Intervention
G Năstase
Jurnalul de Chirurgie (2023) Vol. 19, Iss. 4, pp. 314-320
Open Access
Page 1

Scroll to top